CNS Pharmaceuticals Inc
CNSP6.580USD
-0.100-1.50%
收盤 12/19, 16:00（美東）報價延遲15分鐘
3.78M總市值
0.02本益比TTM
關於 CNS Pharmaceuticals Inc 公司
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc簡介
公司代碼CNSP
公司名稱CNS Pharmaceuticals Inc
上市日期Nov 08, 2019
CEOClimaco (John Michael)
員工數量4
證券類型Ordinary Share
年結日Nov 08
公司地址2100 West Loop S Ste 900
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編77027-3522
電話18009469185
網址https://cnspharma.com/
公司代碼CNSP
上市日期Nov 08, 2019
CEOClimaco (John Michael)
CNS Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-37.50%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+100.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Mahery
Ms. Amy Mahery
Independent Director
Independent Director
--
-100.00%
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Lead Independent Director
Lead Independent Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-37.50%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+100.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
UBS Financial Services, Inc.
1.63%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
其他
90.69%
持股股東
持股股東
佔比
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
UBS Financial Services, Inc.
1.63%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
其他
90.69%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
5.19%
Investment Advisor
3.90%
Corporation
0.15%
Bank and Trust
0.07%
其他
90.69%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
34
57.74K
7.40%
+32.22K
2025Q3
34
25.52K
7.99%
-17.21K
2025Q2
30
42.73K
1.82%
+37.38K
2025Q1
30
5.15K
1.78%
+786.00
2024Q4
28
5.89K
1.26%
+3.16K
2024Q3
24
2.73K
0.48%
+2.49K
2024Q2
21
240.00
1.54%
+206.00
2024Q1
23
34.00
3.95%
+20.00
2023Q4
20
11.00
4.00%
+6.00
2023Q3
22
5.00
7.14%
--
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
UBS Financial Services, Inc.
2.67K
0.47%
+677.00
+33.88%
Jun 30, 2025
Cortice Biosciences, Inc.
956.00
0.17%
+956.00
--
Jul 30, 2024
Barrett & Company, Inc.
8.00
0%
--
--
Jun 30, 2025
Climaco (John Michael)
8.00
0%
--
--
May 09, 2025
BofA Global Research (US)
4.00
0%
+3.00
+300.00%
Jun 30, 2025
Downs (Christopher)
3.00
0%
--
--
May 09, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
公告日期
類型
比率
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Nov 28, 2022
Merger
30→1
查看更多
常見問題
CNS Pharmaceuticals Inc的前五大股東是誰？
CNS Pharmaceuticals Inc的前五大股東如下：
UBS Financial Services, Inc.持有股份：2.67K佔總股份比例：0.47%。
Cortice Biosciences, Inc.持有股份：956.00佔總股份比例：0.17%。
Barrett & Company, Inc.持有股份：8.00佔總股份比例：0.00%。
Climaco (John Michael)持有股份：8.00佔總股份比例：0.00%。
BofA Global Research (US)持有股份：4.00佔總股份比例：0.00%。
UBS Financial Services, Inc.持有股份：2.67K佔總股份比例：0.47%。
Cortice Biosciences, Inc.持有股份：956.00佔總股份比例：0.17%。
Barrett & Company, Inc.持有股份：8.00佔總股份比例：0.00%。
Climaco (John Michael)持有股份：8.00佔總股份比例：0.00%。
BofA Global Research (US)持有股份：4.00佔總股份比例：0.00%。
CNS Pharmaceuticals Inc的前三大股東類型是什麼？
CNS Pharmaceuticals Inc 的前三大股東類型分別是：
Stonepine Capital Management, LLC
DRW Securities, LLC
UBS Financial Services, Inc.
Stonepine Capital Management, LLC
DRW Securities, LLC
UBS Financial Services, Inc.
有多少機構持有CNS Pharmaceuticals Inc(CNSP)的股份？
截至2025Q4，共有34家機構持有CNS Pharmaceuticals Inc的股份，合計持有的股份價值約為57.74K，占公司總股份的7.40% 。與2025Q3相比，機構持股有所增加，增幅為-0.59%。
哪個業務部門對CNS Pharmaceuticals Inc的收入貢獻最大？
在--，--業務部門對CNS Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
